

SUMMARY

Total Settlements Reached:
Over \$776 Million

Purchase Date Range:
Various

Filing Deadlines:
Various

*Specific information about the class
action(s) listed below*

IS YOUR BUSINESS A THIRD-PARTY PAYOR THAT PURCHASED, PAID FOR, AND/OR PROVIDED REIMBURSEMENT FOR PRESCRIPTION DRUGS?

YOU MAY BE ELIGIBLE TO RECOVER MONEY!

If you are a Third-Party Payor (“TPP”) and purchased, paid for, and/or provided reimbursement for prescription drugs, you may be eligible to recover from one or more of the dozens of class action lawsuits that involve the sale or purchase of pharmaceuticals. Generally, TPPs are insurance companies, healthcare benefit providers, health maintenance organizations, union health and welfare plans, self-funded health and welfare plans, and any other health benefit provider and/or entity that contracts with a health insurance company or other entity to serve as a third-party claims administrator to administer their prescription drug benefits. TPPs also include entities that may provide prescription drug benefits for current or former public employees and/or retirees and private entities that provide pharmacy benefits for a state Medicaid program or Medicare Part D, but only to the extent that the entity was at risk for the cost of the payment(s). This definition may vary per class action.

**THIS IS NOT AN OFFICIAL COURT NOTICE.
INFORMATION CONTAINED IN THIS SUMMARY IS SUBJECT TO CHANGE.**

CLASS ACTION SUMMARY

THIRD-PARTY PAYOR ANTITRUST CLASS ACTIONS

Current Class Actions

Below is a list of antitrust class actions in which FRS is currently filing claims and/or anticipating filing claims in the future on behalf of its clients. FRS will require the contact information of your Pharmacy Benefit Manager in order to complete your TPP claim. The classes are nationwide unless otherwise indicated, and the covered period dates may vary by jurisdiction (consumers may be eligible to participate in some of the Settlements listed below, though their eligibility requirements may differ from those listed in this summary). *An asterisk indicates that some of the Defendants have not settled to date, and therefore, the fund may increase:

Settlement (Drug or Brand Name)	Funds	Covered Period	Claim Filing Deadline
cART Regimen (Altripla, Complera, Evotaz, Stribild and Truvada)*	\$10,000,000	05/14/15 – 10/13/21	No Claim Forms are available at this time and no claim filing deadline has been set. Eligible jurisdictions include: AL, AZ, AR, CA, CT, FL, HI, ID, IL, IA, KS, MD, ME, MA, MI, MN, MS, MO, MT, NE, NV, NH, NM, NY, NC, ND, OR, RI, SD, TN, UT, VT, WV and WI.
Xyrem	\$198,400,000	01/01/17 – Present	The deadline to file a claim has passed. Claims may still be filed. Acceptance is subject to Court approval.
Generic Pharma Indirect (End Payor Settlements with Sandoz/ Fougera, Apotex, Heritage and Sun/Taro)*	\$533,000,000	05/01/09 –12/31/19	No Claim Forms are available at this time and no claim filing deadline has been set. Please contact FRS for additional information on the named generic drugs that are included in this settlement.
QVAR	\$35,000,000	01/01/15 – 07/31/25	No Claim Forms are available at this time and no claim filing deadline has been set. Eligible jurisdictions include: District of Columbia, AK, AZ, AR, CA, CT, DE, FL, HI, IL, IN, IA, KS, ME, MD, MA, MI, MN, MS, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, RI, SD, TN, TX, UT, VT, VA, WA, WV, WI and WY.

Pharmaceutical-Related Antitrust Class Actions

FRS is monitoring the following actions that have been granted class certification. It is impossible to predict the outcome of these litigations; however, it is possible that money may become available to eligible class members if settlements are reached with the respective Defendant(s) or the cases proceed to trial. Please contact FRS for additional information (e.g., the list of excluded parties) about these class actions.

Drug or Brand Name	Class Definition
CVS	All health plans that had Caremark, L.L.C., Express Scripts, Medco, or MedImpact (or any of their predecessors) as their pharmacy benefit managers and paid for generic prescription drugs purchased from CVS that were included in CVS's Health Savings Pass program in AR, CO, CT, District of Columbia, HI, IL, IN, IA, MO, NM, NY, OK and WV and paid for those drugs based on a formula containing Usual and Customary price from November 1, 2008 through February 1, 2016. The litigation relates to TPPs that paid for CVS generic prescription drugs listed on the CVS Health Savings Pass prescription drug medication list.
Actos TPP (RICO)	All third-party payors in the United States and its territories, that purchased, paid for, and/or reimbursed all or any portion of the price for Actos, ActosPlus MET, ActosPlus MET XR, Duetact, and/or Oseni, for 5 or more independent prescriptions, between July 1, 1999 and September 17, 2010, for purposes other than resale.
Actos TPP (Pioglitazone)	All entities that, for consumption by their members, insureds, or beneficiaries, paid and/or provided reimbursement for some or all of the purchase price of Actos or generic pioglitazone in the District of Columbia, Puerto Rico, AZ, CA, IL, IA, ME, MI, MN, MS, NE, NV, NH, NM, NC, ND, OR, RI, SD, UT, WV and WI, other than for resale, at any time from January 17, 2011 through and until December 31, 2015; and all individuals who paid for some or all of the purchase price of Actos in the District of Columbia, Puerto Rico, AZ, CA, IL, IA, ME, MI, MN, MS, NE, NV, NH, NM, NC, ND, OR, RI, SD, UT, WV and WI at any time from January 17, 2011 through and until December 31, 2015.
Valsartan (Losartan and Irbesartan)	All third-party payors that, from at least January 1, 2012 through the date of final recall as of November 10, 2021, paid any amount of money in AK, AZ, CA, CO, CT, DE, FL, HI, ID, IL, KY, LA, ME, MA, MN, MO, NE, NH, NM, NY, NC, ND, OK, OR, PA, SD, TX, VA or WA for a Valsartan-containing drug that was manufactured by any Active Pharmaceutical Ingredient or Finished Dose Manufacturer Defendant and distributed or sold in the United States by any Active Pharmaceutical Ingredient, Finished Dose or Wholesaler Defendant.
Tracleer (Bosentan)	All entities that, for consumption by their members, employees, insureds, participants or beneficiaries, purchased, paid and/or provided reimbursement for some or all of the purchase price of Tracleer or Bosentan, other than for resale, in AZ, CA, FL, IL, IA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NM, NY, NC, ND, OR, RI, SC, SD, UT, VT, VA, WV, WI, District of Columbia and/or Puerto Rico, from December 29, 2015 through September 6, 2024.
Generic Pharma Indirect (Clobetasol)	All third-party payors who indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price for Defendants' generic Clobetasol products (generic clobetasol propionate cream, emollient cream, ointment, solution and gel) purchased in the District of Columbia, the U.S. Virgin Islands, AK, AZ, AR, CA, CO, CT, DE, FL, HI, IA, KS, ME, MD, MA, MI, MN, MS, MO, NE, NV, NH, NJ, NM, NY, NC, ND, OR, RI, SD, TN, UT, VT, VA, WV or WI at retail or via mail-order, for personal use by their members, enrollees or beneficiaries and not for resale from September 1, 2014 through December 31, 2018.
Generic Pharma Indirect (Clomipramine)	All third-party payors who indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price for Defendants' generic Clomipramine products (generic clomipramine hydrochloride 25, 50, or 75 mg capsules) purchased in the District of Columbia, the U.S. Virgin Islands, AK, AZ, AR, CA, CO, CT, DE, FL, HI, IA, KS, ME, MD, MA, MI, MN, MS, MO, NE, NV, NH, NJ, NM, NY, NC, ND, OR, RI, SD, TN, UT, VT, VA, WV or WI at retail or via mail-order, for personal use by their members, enrollees or beneficiaries and not for resale from August 1, 2013 through December 31, 2018.
Opiates TPP (RICO)	All entities that paid and/or were reimbursed for (i) opioid prescription drugs manufactured, marketed, sold, distributed, or dispensed by any of the Defendants and/or Opioid Supply Chain Members for purposes other than resale, and/or (ii) paid or incurred costs for treatment related to the misuse, addiction and/or overdose of opioid drugs, on behalf of individual beneficiaries, insureds, and/or members, during the time period of January 1, 1996 to September 3, 2024.
Stelara TPP	All third-party payors who indirectly purchased or paid for, as part of a prescription drug benefit, some or all of the purchase price for Stelara in AL, AZ, CA, CT, FL, HI, IL, IA, KS, ME, MD, MI, MN, MS, NE, NV, NH, NM, NY, NC, ND, OR, RI, SD, TN, UT, VT, WV, WI, District of Columbia and/or Puerto Rico for personal use by their members, enrollees or beneficiaries, from January 1, 2024 through December 31, 2025.

**THIRD-PARTY PAYOR
ANTITRUST CLASS ACTIONS**

Pharmaceutical-Related Antitrust Class Actions

Below is a list of actions that do not have a certified class at this time. It is impossible to predict the outcome of these litigations; however, it is possible that money may become available to eligible class members, if the classes are certified and settlements are reached with the respective Defendant(s) or the cases proceed to trial. Please contact FRS for additional information about these class actions.

Acetazolamide	Capecitabine	Diphenoxylate/Atropine	Glumetza	Nadolol	Propranolol
Acetazolamide ER	Captopril	Disopyramide Phosphate	Glyburide	Nafcillin Sodium	Propranolol ER
Acthar	Carbamazepine	Divalproex ER	Glyburide/Metformin	Naproxen Sodium	Raloxifene HCL
Adapalene	Carbamazepine ER	Doxazosin Mesylate	Griseofulvin	Neomycin/Polymyxin/ Hydrocortisone	Ranitidine HCL
Albuterol	Carisoprodol	Doxycycline Hyclate	Halobetasol Propionate	Niacin ER	RotaTeq
Alclometasone Dipropionate	Cefdinir	Doxycycline Hyclate DR	Haloperidol	Niaspan	Silver Sulfadiazine
Allopurinol	Cefpodoxime Proxetil	Doxycycline Monohydrate	Hydrocortisone Acetate	Nimodipine	Soliris
Amantadine HCL	Cefprozil	Drospirenone/Ethinyl Estradiol (Ocella)	Hydrocortisone Valerate	Nitrofurantoin/Macrocrystalline	Spiriva Respimat
Amiloride HCL/HCTZ	Cefuroxime Axetil	Econazole	Hydroxyurea	Norethindrone Acetate	Spironolactone/HCTZ
Amitiza	Celebrex	Enalapril Maleate	Hydroxyzone Pamoate	Norethindrone/Ethinyl Estradiol (Balziva)	Tacrolimus
Amitriptyline	Celecoxib	Entecavir	Imiquimod	Nortriptyline HCL	Tamoxifen Citrate
Ammonium Lactate	Cephalexin (Cefalexin)	Eplerenone	Irbesartan	Nuvigil	Tecfidera
Amoxicillin/Clayulanate Potassium	Chlorpromazine HCL	Erythromycin	Isoniazid	Nystatin	Temozolomide
Amphetamine/Dextroamphetamine (MAS) (Adderall)	Cholestyramine	Estazolam	Isosorbide Dinitrate	Nystatin/Triamcinolone Acetonide	Terconazole
Amphetamine/Dextroamphetamine ER (MAS)	Ciclopirox	Estradiol	Ketoconazole	Opoids	Theophylline ER
Atenolol Chlorthalidone	Cimetidine	Estradiol/ Norethindrone Acetate (Mimvey)	Ketoprofen	Omega 3 Acid Ethyl Esters	Timolol Maleate
Atripila	Ciprofloxacin HCL	Ethambutol HCL	Ketorolac Tromethamine	Oxacillin Sodium	Tizanidine HCL
Atropine Sulfate	Clarithromycin ER	Ethinyl Estradiol/Desogestrel (Kariva)	Labeltalol HCL	Oxaprozin	Tobramycin
Azithromycin	Clemastine Fumarate	Ethinyl Estradiol/ Levonorgestrel (Portia, Jolessa)	Lamivudine/Zidovudine (Combivir)	Oxybutynin Chloride	Tobramycin/Dexamethasone
Baclofen	Clindamycin Phosphate	Ethosuximide	Latanoprost	Oxycodone/Acetaminophen	Tolmetin Sodium
Balsalazide Disodium	Clonidine	Etodolac	Leflunomide	Oxycodone HCL	Tolterodine Tartrate
Benazepril HCTZ	Clotrimazole	Etodolac ER	Levothyroxine	Paricalcitol	Tolterodine Tartrate ER
Betamethasone Dipropionate	Colcrys	Exemestane	Lidocaine HCL	Paromomycin	Topical Corticosteroids
Betamethasone Dipropionate Augmented	Combivent Respimat	Exforge	Lidocaine/ Prilocaine	Penicillin V Potassium	Topiramate
Betamethasone Dipropionate/ Clotrimazole	Copaxone	Eylea	Lipitor	Pentoxifylline ER	Trazodone HCL
Betamethasone Valerate	Cyproheptadine HCL	Fenofibrate	Loperamide HCL	Permethrin	Triamcinolone Acetonide
Bethanechol Chloride	Desmopressin Acetate	Fluconazole	Medroxyprogesterone Acetate	Perphenazine	Triamterene/HCTZ
Bromocriptine Mesylate	Desogestrel and Ethinyl Estradiol [Kariva]	Fluocinolone Acetonide	Meprobamate	Phenytoin Sodium ER	Trifluoperazine HCL
Budesonide	Desonide	Fluocinonide	Metformin (F) ER	Pilocarpine HCL	Ursodiol
Budesonide DR	Dexlansoprazole HCL ER [Focalin]	Fluoxetine HCL	Methadone HCL	Pioglitazone Metformin HCL	Valsartan HCTZ
Bumetanide	Dextroamphetamine Sulfate	Flurbiprofen	Methazolamide	Piroxicam	Varenicline
Buspiron HCL	Dextroamphetamine Sulfate ER	Flutamide	Methimazole	Potassium Chloride ER	Vascepa
Butorphanol Tartrate	Diclofenac Potassium	Fluticasone Propionate	Methotrexate	Pravastatin	Verapamil
Cabergoline	Dicloxacillin Sodium	Fluvastatin Sodium	Methylphenidate	Prazosin HCL	Verapamil SR
Calcipotriene	Diflunisal	Fosinopril HCTZ	Methylphenidate ER	Prednisolone Acetate	Vumerity
Calcipotriene Betamethasone Dipropionate	Digoxin	Gabapentin	Methylprednisolone	Prednisone	Warfarin Sodium
	Diltiazem HCL	Glimepiride	Metronidazole	Prescription Drugs**	Zoledronic Acid
		Glipizide/Metformin	Moexipril HCL/HCTZ	Prochlorperazine	
			Mometasone Furoate	Promethazine	
			Nabumetone		

**The litigation relates to purchases and/or reimbursement for prescription drugs other than or in addition to insulin dispensed at an affiliated pharmacy.

The Services FRS Provides: Financial Recovery Strategies (FRS) is a class action claims management consultant; we are not a court appointed claims administrator or class counsel. If you hire FRS, FRS will work within your guidelines to manage the claims process. The services that FRS provides include the following: (i) notifying you when we believe that you may be eligible to participate in settlements likely to be valuable to you; (ii) endeavoring to enhance the likelihood that all of your eligible business units (e.g., subsidiaries, divisions, acquisitions and divestitures) are included in the claims process; (iii) to reduce the support needed from your in-house staff, providing advice on what, if any, documents need to be collected and maintained, and, when requested, assisting in that effort; (iv) when required documents are not available or are too burdensome to collect, attempting to develop innovative alternatives to satisfy documentation requirements and striving to obtain approval of those alternatives; (v) preparing, assembling and submitting your claim package, and managing it throughout the claims processing phase, including working with you to address any concerns or questions claims administrators may have; (vi) providing regular updates on the recovery process; (vii) reviewing your payment to assure that it has not been under calculated; and (viii) following up with you to assure that your recovery check is deposited. FRS's recovery specialists are always available to answer any questions you may have.

How to Retain FRS: If you wish to hire FRS to file and manage a claim on your behalf, you must return a signed Claims Management Agreement and a signed Authority to File and Manage Claims. Before doing so, it is important that you understand their terms and make sure that all information about you is correct.